Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | FABP1 | P07148 | 1/20 | 0.51 |
| ▸ | FABP6 | P51161 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13316893 | 0.86 | FAAH (0.56) | LMNAMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL8249106 | 0.84 | MEN1 (0.56) | LMNAMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL8246350 | 0.83 | MEN1 (0.52) | LMNAMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL8245728 | 0.82 | ALDH1A1 (0.55) | LMNAMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL5600177 | 0.81 | MEN1 (0.67) | LMNAMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL3614199 | 0.79 | LMNA (0.65) | LMNAMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL8249156 | 0.78 | SLC6A7 (0.54) | MEN1KMT2AALDH1A1KDM4EGAA | |
| SCHEMBL13316927 | 0.77 | PTGS2 (0.56) | LMNAALDH1A1KDM4EPKMSMN1; SMN2 | |
| SCHEMBL13973332 | 0.76 | MEN1 (0.68) | LMNAMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL13959022 | 0.75 | MEN1 (0.67) | LMNAMEN1KMT2AALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100152188-A1 | Novel Heterocyclic Compounds | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2010-06-17 | — | — | US | disclosed |
| US-20100152188-A1 | Novel Heterocyclic Compounds | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152188-A1 | Novel Heterocyclic Compounds | CYP11B2, CYP3A5, CYP11B1 | LMNA 3772/4885MEN1 116/4885KMT2A 4019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.